ATE296292T1 - Piperazin-derivate und ihre verwendung als entzündungshemmende mittel - Google Patents

Piperazin-derivate und ihre verwendung als entzündungshemmende mittel

Info

Publication number
ATE296292T1
ATE296292T1 AT02090193T AT02090193T ATE296292T1 AT E296292 T1 ATE296292 T1 AT E296292T1 AT 02090193 T AT02090193 T AT 02090193T AT 02090193 T AT02090193 T AT 02090193T AT E296292 T1 ATE296292 T1 AT E296292T1
Authority
AT
Austria
Prior art keywords
inflammatory agents
piperazine derivatives
compounds
directed
humans
Prior art date
Application number
AT02090193T
Other languages
German (de)
English (en)
Inventor
John G Bauman
Brad O Buckman
Josep E Hesselgasser
Ameen F Ghannam
Richard Horuk
Imadul Islam
Meina Liang
Karen B May
Sean D Monahan
Michael M Morissey
Howarfd P Ng
Gua Ping Wei
Wie Xu
Wie Zheng
Kenneth J Shaw
Zhao Zuchun
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Application granted granted Critical
Publication of ATE296292T1 publication Critical patent/ATE296292T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AT02090193T 1997-06-12 1998-06-11 Piperazin-derivate und ihre verwendung als entzündungshemmende mittel ATE296292T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87359997A 1997-06-12 1997-06-12
US09/094,397 US6207665B1 (en) 1997-06-12 1998-06-09 Piperazine derivatives and their use as anti-inflammatory agents

Publications (1)

Publication Number Publication Date
ATE296292T1 true ATE296292T1 (de) 2005-06-15

Family

ID=26788818

Family Applications (2)

Application Number Title Priority Date Filing Date
AT02090193T ATE296292T1 (de) 1997-06-12 1998-06-11 Piperazin-derivate und ihre verwendung als entzündungshemmende mittel
AT98937467T ATE232522T1 (de) 1997-06-12 1998-06-11 Piperazin-derivate und ihre verwendung als entzündungshemmende mittel

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT98937467T ATE232522T1 (de) 1997-06-12 1998-06-11 Piperazin-derivate und ihre verwendung als entzündungshemmende mittel

Country Status (22)

Country Link
US (8) US6207665B1 (US20030139425A1-20030724-C00009.png)
EP (2) EP1254899B1 (US20030139425A1-20030724-C00009.png)
JP (1) JP2002503239A (US20030139425A1-20030724-C00009.png)
KR (1) KR100549137B1 (US20030139425A1-20030724-C00009.png)
AT (2) ATE296292T1 (US20030139425A1-20030724-C00009.png)
AU (1) AU735462B2 (US20030139425A1-20030724-C00009.png)
CA (1) CA2293382C (US20030139425A1-20030724-C00009.png)
CZ (1) CZ295784B6 (US20030139425A1-20030724-C00009.png)
DE (2) DE69811363T2 (US20030139425A1-20030724-C00009.png)
DK (2) DK0988292T3 (US20030139425A1-20030724-C00009.png)
EA (2) EA200200262A1 (US20030139425A1-20030724-C00009.png)
EE (4) EE200200683A (US20030139425A1-20030724-C00009.png)
ES (2) ES2191320T3 (US20030139425A1-20030724-C00009.png)
HU (1) HUP0003929A3 (US20030139425A1-20030724-C00009.png)
IL (1) IL132398A (US20030139425A1-20030724-C00009.png)
IS (1) IS2241B (US20030139425A1-20030724-C00009.png)
NO (2) NO317343B1 (US20030139425A1-20030724-C00009.png)
PL (1) PL337758A1 (US20030139425A1-20030724-C00009.png)
PT (1) PT1254899E (US20030139425A1-20030724-C00009.png)
SK (2) SK285162B6 (US20030139425A1-20030724-C00009.png)
TR (1) TR199903034T2 (US20030139425A1-20030724-C00009.png)
WO (1) WO1998056771A2 (US20030139425A1-20030724-C00009.png)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207665B1 (en) * 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
AU2740900A (en) * 1999-01-29 2000-08-18 Millennium Pharmaceuticals, Inc. Method of treating demyelinating inflammatory disease using ccr1 antagonists
IL151923A0 (en) 2000-03-31 2003-04-10 Pfizer Prod Inc Novel piperazine derivatives
LT5132B (lt) 2000-07-31 2004-05-25 Schering Aktiengesellschaft Nepeptidiniai ccr1 receptorių antagonistai derinyje su ciklosporinu a širdies transplanto atmetimui gydyti
US6740636B2 (en) * 2000-07-31 2004-05-25 Schering Aktiengesellschaft Non-peptide CCR1 receptor antagonists in combination with cyclosporin A for the treatment of heart transplant rejection
US20020173524A1 (en) * 2000-10-11 2002-11-21 Tularik Inc. Modulation of CCR4 function
IL154912A0 (en) * 2000-10-19 2003-10-31 Pfizer Prod Inc Bridged piperazine derivatives
UY27003A1 (es) 2000-11-06 2002-07-31 Schering Ag Productos radiofarmacéuticos para el diagnóstico de la enfermedad de alzheimer
US7144903B2 (en) * 2001-05-23 2006-12-05 Amgen Inc. CCR4 antagonists
US6861424B2 (en) 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
MXPA03011954A (es) 2001-06-20 2004-03-26 Pfizer Prod Inc Nuevos derivados de acido sulfonico.
CA2450475A1 (en) * 2001-06-20 2003-01-03 Linda Brockunier Dipeptidyl peptidase inhibitors for the treatment of diabetes
US6812230B2 (en) * 2001-08-07 2004-11-02 Schering Aktiengesellschaft Non-peptide CCR1 receptor antagonists for the treatment of progressive renal fibrosis
US7718802B2 (en) 2001-08-10 2010-05-18 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
US7655658B2 (en) * 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
US7732451B2 (en) * 2001-08-10 2010-06-08 Palatin Technologies, Inc. Naphthalene-containing melanocortin receptor-specific small molecule
US7456184B2 (en) * 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
US7354923B2 (en) * 2001-08-10 2008-04-08 Palatin Technologies, Inc. Piperazine melanocortin-specific compounds
JP2005504043A (ja) * 2001-08-10 2005-02-10 パラチン テクノロジーズ インク． 生物学的に活性な金属ペプチド類のペプチド模倣体類
DE10152351B4 (de) * 2001-10-18 2005-09-22 Schering Ag Feste Arzneimittelformulierung für ein Piperazinharnstoffderivat
US20030087913A1 (en) * 2001-10-18 2003-05-08 Schering Ag Solid pharmaceutical agent formulation for a piperazine urea derivative
EA006243B1 (ru) * 2001-10-22 2005-10-27 Пфайзер Продактс Инк. Производные пиперазина с антагонистической активностью к рецептору ccr1
KR100472086B1 (ko) * 2001-11-23 2005-02-21 한국화학연구원 항산화 활성을 갖는 3,5-디알콕시-4-히드록시페닐기로치환된 피페라진 유도체, 그의 제조방법 및 이를 포함하는약학적 조성물
GB0203299D0 (en) * 2002-02-12 2002-03-27 Glaxo Group Ltd Novel compounds
TW200400035A (en) 2002-03-28 2004-01-01 Glaxo Group Ltd Novel compounds
GB0207447D0 (en) * 2002-03-28 2002-05-08 Glaxo Group Ltd Novel compounds
US20050256130A1 (en) * 2002-06-12 2005-11-17 Chemocentryx, Inc. Substituted piperazines
CN1867336B (zh) * 2002-06-12 2010-05-12 凯莫森特里克斯股份有限公司 1-芳基-4-取代的哌嗪衍生物及其制药用途
US7589199B2 (en) * 2002-06-12 2009-09-15 Chemocentryx, Inc. Substituted piperazines
US6727241B2 (en) * 2002-06-12 2004-04-27 Chemocentryx Anti-inflammatory compositions and methods of use
US7842693B2 (en) * 2002-06-12 2010-11-30 Chemocentryx, Inc. Substituted piperazines
US20040092529A1 (en) * 2002-10-30 2004-05-13 Pfizer Inc Methods of using piperazine derivatives
PL377053A1 (pl) 2002-12-11 2006-01-23 Schering Aktiengesellschaft Związki 2-aminokarbonylo-chinoliny jako antagonisty receptora płytkowego difosforanu adenozyny
BR0317244A (pt) * 2002-12-13 2005-11-01 Pfizer Prod Inc Derivados de piperazina contendo fósforo como antagonistas ccr1
US7968548B2 (en) 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
US7727990B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine and keto-piperazine compounds
US7727991B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Substituted melanocortin receptor-specific single acyl piperazine compounds
WO2005102340A1 (en) * 2003-05-30 2005-11-03 Palatin Technologies, Inc. Piperazine melanocortin-specific compounds
AU2004266153A1 (en) * 2003-08-22 2005-03-03 Bayer Schering Pharma Aktiengesellschaft Chemokine inhibiting piperazine derivatives and their use to treat myocarditis
AR045536A1 (es) 2003-08-29 2005-11-02 Ranbaxy Lab Ltd Inhibidores de la fosfodiesterasa tipo -iv
US8071134B2 (en) 2003-09-15 2011-12-06 Ordway Research Institute, Inc. Thyroid hormone analogs and methods of use
US8668926B1 (en) 2003-09-15 2014-03-11 Shaker A. Mousa Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
US9198887B2 (en) 2003-09-15 2015-12-01 Nanopharmaceuticals Llc Thyroid hormone analogs and methods of use
EP2335694B1 (en) 2003-09-15 2018-06-13 NanoPharmaceuticals LLC Thyroid hormone analogs and methods of use
EP1713483A1 (en) * 2004-02-06 2006-10-25 Schering Aktiengesellschaft Chemokine inhibiting piperazine derivatives and their use to treat multiple myeloma
EP1727526A2 (en) * 2004-02-24 2006-12-06 Schering Aktiengesellschaft Piperazine urea derivatives for the treatment of endometriosis
SE0400441D0 (sv) 2004-02-25 2004-02-25 Active Biotech Ab Novel Benzofurans and Indols
SE0400440D0 (sv) * 2004-02-25 2004-02-25 Active Biotech Ab Novel Cinnamic Amides
US7435831B2 (en) * 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
CA2558211C (en) * 2004-03-03 2013-09-03 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
US7709484B1 (en) 2004-04-19 2010-05-04 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
ES2251292B1 (es) * 2004-04-20 2007-07-01 Inke, S.A. Procedimiento para la obtencion de un compuesto farmaceuticamente activo y de sus intermedios de sintesis.
GB0409236D0 (en) * 2004-04-26 2004-05-26 Novartis Ag Organic compounds
EP1793814B1 (en) 2004-09-15 2015-01-21 NanoPharmaceuticals LLC Thyroid hormone analogs for inhibiting angiogenesis
EP1749519A1 (de) 2005-08-05 2007-02-07 Schering Aktiengesellschaft Arzneiform mit Retardtierter pH-unabhängiger Wirkstofffreisetzung für Wirkstoffe mit starker pH-abhängiger Löslichkeit
US20070087056A1 (en) * 2005-08-09 2007-04-19 Claudia Guthmann Pharmaceutical form with sustained pH-independent active ingredient release for active ingredients having strong pH-dependent solubility
US9498536B2 (en) 2005-09-15 2016-11-22 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating anti-inflammatory disorders
US10130686B2 (en) 2005-09-15 2018-11-20 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating inflammatory disorders
WO2007035612A2 (en) 2005-09-16 2007-03-29 Ordway Research Institute, Inc. Polyphenol conjugates as rgd-binding compounds and methods of use
JP4855478B2 (ja) * 2005-12-01 2012-01-18 エフ．ホフマン−ラ ロシュ アーゲー Ｌ−ｃｐｔ１阻害剤としてのヘテロアリール置換されたピペリジン誘導体
MX2008014450A (es) * 2006-05-18 2009-03-09 Mannkind Corp Inhibidores de cinasa intracelular.
FR2902426B1 (fr) * 2006-06-19 2008-09-05 Pierre Fabre Medicament Sa Derives de cinnamoyl-piperazine
US7834017B2 (en) 2006-08-11 2010-11-16 Palatin Technologies, Inc. Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
CN101595102B (zh) 2006-10-18 2013-08-07 辉瑞产品公司 二芳基醚脲化合物
ES2535005T3 (es) 2006-12-22 2015-05-04 Nanopharmaceuticals Llc Formulaciones de nanopartículas y de polímeros para análogos, antagonistas y formulaciones de la hormona tiroidea, y usos de los mismos
WO2008090357A2 (en) * 2007-01-24 2008-07-31 Palatin Technologies, Inc. N, n; -substituted piperazines binding to melanocortin receptor
EP1958947A1 (en) 2007-02-15 2008-08-20 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type 4
US9180107B2 (en) 2009-03-31 2015-11-10 Nanopharmaceuticals Llc Combination treatment of cancer with cetuximab and tetrac
EP2442800B1 (en) 2009-06-17 2019-04-24 NanoPharmaceuticals LLC Nanoparticle and polymer formulations for thyroid hormone, analogs, antagonists, and formulations and uses thereof
PT3002008T (pt) 2010-03-11 2018-12-24 Univ New York Compostos de amido como moduladores roryt e suas utilizações
US8802240B2 (en) 2011-01-06 2014-08-12 Nanopharmaceuticals Llc Uses of formulations of thyroid hormone analogs and nanoparticulate forms thereof to increase chemosensitivity and radiosensitivity in tumor or cancer cells
KR101380466B1 (ko) * 2011-09-27 2014-04-02 한국생명공학연구원 ＨＩＦ―１α 활성을 저해하는 신규 화합물 및 그 제조방법
CN102408395B (zh) * 2011-10-24 2014-04-02 广西师范大学 新的哌嗪和高哌嗪类衍生物及其制备方法和应用
CA2852160A1 (en) 2011-10-28 2013-05-02 Galderma Research & Development New leukocyte infiltrate markers for rosacea and uses thereof
US20140221335A1 (en) 2013-02-06 2014-08-07 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9115093B2 (en) 2013-03-04 2015-08-25 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
EP3022202B1 (en) 2013-07-18 2019-05-15 Novartis AG Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core
CN103724296B (zh) * 2013-12-12 2015-09-02 南京医科大学 芳基取代的哌嗪羰基衍生物及其制备方法和应用
EP3153014B1 (en) * 2014-06-06 2020-12-30 Riken Agent for inducing plant callus and method for inducing plant callus
CN105218501A (zh) * 2014-07-03 2016-01-06 南京大学 含哌嗪环的香豆素类衍生物及其制备与在抗菌药物中的应用
US9475779B2 (en) 2014-07-31 2016-10-25 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9657015B2 (en) 2014-07-31 2017-05-23 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
JP6749002B2 (ja) 2014-10-08 2020-09-02 国立研究開発法人理化学研究所 植物成長促進剤及び植物成長促進方法
CN107709314A (zh) 2015-06-11 2018-02-16 巴斯利尔药物国际股份公司 外排泵抑制剂及其治疗性用途
JP7074749B2 (ja) 2016-06-07 2022-05-24 ナノファーマシューティカルズ エルエルシー αｖβ３インテグリン甲状腺アンタゴニストにコンジュゲートした非開裂性ポリマー
US11548893B2 (en) 2017-07-15 2023-01-10 Arisan Therapeutics Inc. Enantiomerically pure adamantane carboxamides for the treatment of filovirus infection
US10328043B1 (en) 2018-04-11 2019-06-25 Nanopharmaceuticals, Llc. Composition and method for dual targeting in treatment of neuroendocrine tumors
US11351137B2 (en) 2018-04-11 2022-06-07 Nanopharmaceuticals Llc Composition and method for dual targeting in treatment of neuroendocrine tumors
CN110372638B (zh) * 2018-04-13 2023-09-22 中国药科大学 哌嗪类ampk激动剂及其医药用途
CN108484558A (zh) * 2018-05-14 2018-09-04 中国药科大学 黄酮类ampk激动剂及其医药用途
US10961204B1 (en) 2020-04-29 2021-03-30 Nanopharmaceuticals Llc Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention into brain tumors
AU2022287943A1 (en) * 2021-06-07 2023-12-07 Nanopharmaceuticals Llc Composition and method for dual targeting in treatment of neuroendocrine tumors
EP4115885A1 (en) 2021-07-05 2023-01-11 Charité - Universitätsmedizin Berlin A pharmaceutical composition comprising bay 86-5277 and salts thereof for use in the treatment of viral infections and hyperinflammation
US11723888B2 (en) 2021-12-09 2023-08-15 Nanopharmaceuticals Llc Polymer conjugated thyrointegrin antagonists
WO2023235297A1 (en) * 2022-06-03 2023-12-07 Imbria Pharmaceuticals, Inc. Compounds and methods for increasing efficiency of cardiac metabolism

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3324117A (en) 1967-06-06 Carboxylic acid piperazides and process for their manufacture
FR7524M (US20030139425A1-20030724-C00009.png) 1968-03-12 1969-12-15
DE2304155A1 (de) * 1973-01-29 1974-08-01 Ichthyol Ges Cordes Hermanni & N-acylierte substituierte piperazinbzw. homopiperazinderivate, sowie verfahren zu ihrer herstellung
DE2730174C2 (de) 1977-07-04 1981-12-10 Ludwig Merckle Kg Chem. Pharm. Fabrik, 7902 Blaubeuren Aminobenzoesäurederivate und Arzneimittel enthaltend solche Aminobenzoesäurederivate
EP0018497B1 (de) * 1979-04-06 1982-04-28 Bayer Ag Azolyloxy-essigsäureamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Herbizide
IT1151533B (it) 1982-03-29 1986-12-24 Ravizza Spa Procedimento per la preparazione di p. clorofenossiacetil-piperonilpiperazina
IT1151532B (it) 1982-03-29 1986-12-24 Ravizza Spa Procedimento per la preparazione di p. clorofenossiacetil-piperonilpiperazina
US4439606A (en) * 1982-05-06 1984-03-27 American Cyanamid Company Antiatherosclerotic 1-piperazinecarbonyl compounds
DE3685829T2 (de) 1985-02-04 1992-12-17 Searle & Co Heterocyclische amide.
DE3614363A1 (de) 1986-04-28 1987-10-29 Hoechst Ag Benzothiazinon-derivate, verfahren zu ihrer herstellung, sie enthaltende arzneimittel und deren verwendung
JPS6314774A (ja) 1986-07-07 1988-01-21 Mitsubishi Chem Ind Ltd ピリダジノン誘導体又はその塩類
CN1030415A (zh) 1987-02-20 1989-01-18 山之内制药株式会社 饱和的杂环碳酰胺衍生物和它的制备方法
FR2611713B1 (fr) * 1987-02-27 1990-11-30 Adir Nouveaux derives de l'acide (dihydro-2,3 oxo-2 benzofurannyl-3)-2 acetique, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
AU584502B2 (en) 1987-03-30 1989-05-25 Shosuke Okamoto Phenylalanine derivatives and proteinase inhibitor
CS260089B1 (cs) 1987-05-12 1988-11-15 Miroslav Protiva Piperazidy methoxyfenoxyoctových kyselin a jejich hydrochloridy
AT389112B (de) 1987-10-08 1989-10-25 Hoechst Ag Benzothiazinon-derivate, verfahren zu ihrer herstellung, sie enthaltende arzneimittel und deren verwendung
FR2623808B1 (fr) 1987-12-01 1990-03-09 Adir Nouveaux derives flavonoides (benzyl-4 piperazinyl-1)-2 oxo-2 ethylene substitues, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
NZ228329A (en) 1988-03-18 1991-12-23 Mitsui Toatsu Chemicals Catechol derivatives and pharmaceutical compositions thereof
US5232923A (en) * 1988-03-18 1993-08-03 Mitsui Toatsu Chemicals, Incorporated Catechol derivatives and pharmaceutical preparations containing same
US5010080A (en) 1988-12-02 1991-04-23 G. D. Searle & Co. Use of heterocyclic amides to inhibit tumor metastasis
US5089506A (en) * 1990-04-30 1992-02-18 G. D. Searle & Co. Ethanobicyclic amine derivatives for cns disorders
US5190922A (en) 1991-06-04 1993-03-02 Abbott Laboratories Terminally modified tri-, tetra- and pentapeptide anaphylatoxin receptor ligands
FR2689127B1 (fr) * 1992-03-31 1994-05-06 Adir Cie Nouvelles 3', 5' -ditertbutyl-4'-hydroxy flavones, leur procede de preparation et les compositions pharmaceutiques les renfermant.
US5272175A (en) 1992-05-20 1993-12-21 G. D. Searle & Co. Substituted tyrosyl diamide compounds
US5389645A (en) 1992-08-13 1995-02-14 G. D. Searle & Co. Substituted tyrosyl diamine amide compounds
SK65094A3 (en) 1992-09-03 1995-03-08 Boehringer Ingelheim Kg Aminoacid derivatives, process for producing the same and pharmaceutical compositions containing these derivatives
IL110040A (en) 1993-06-29 2000-07-16 Nissan Chemical Ind Ltd Pyridazinone derivatives their preparation and pharmaceutical compositions comprising them
CA2150345A1 (en) 1993-09-28 1995-04-06 Makoto Komatsu Quinoxaline derivative as antidiabetic agent
IL111730A (en) 1993-11-29 1998-12-06 Fujisawa Pharmaceutical Co Piperazine derivatives, processes for their preparation and pharmaceutical preparations containing them
FR2724656B1 (fr) * 1994-09-15 1996-12-13 Adir Nouveaux derives du benzopyranne, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP4173912B2 (ja) 1995-05-02 2008-10-29 シェーリング コーポレイション ニューロキニンアンタゴニストとしてのピペラジノ誘導体
EP0920306A2 (en) 1996-07-12 1999-06-09 Leukosite, Inc. Chemokine receptor antagonists and methods of use therefor
WO1998004554A1 (fr) 1996-07-29 1998-02-05 Banyu Pharmaceutical Co., Ltd. Antagonistes de recepteurs de chemokines
PL335484A1 (en) 1997-02-26 2000-04-25 Pfizer Derivatives of heteroarylhexamide, their production and application as selective inhibitors of mip-1a being assimilated by its ccr1 receptor
US6207665B1 (en) * 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
JP4783532B2 (ja) 2000-02-05 2011-09-28 バーテックス ファーマシューティカルズ インコーポレイテッド Ｅｒｋのインヒビターとして有用なピラゾール組成物
US6521619B2 (en) 2000-06-29 2003-02-18 Icos Corporation Aryl phenylcyclopropyl sulfide derivatives and their use as cell adhesion inhibiting anti-inflammatory and immune suppressive agents
US6518276B2 (en) 2000-08-31 2003-02-11 Syntex (U.S.A.) Llc 7-oxo-pyridopyrimidines (II)

Also Published As

Publication number Publication date
DK0988292T3 (da) 2003-04-22
DE69811363T2 (de) 2003-11-27
PL337758A1 (en) 2000-09-11
US6534509B1 (en) 2003-03-18
US6977258B2 (en) 2005-12-20
AU735462B2 (en) 2001-07-12
NO20031373L (no) 2000-02-11
EE04056B1 (et) 2003-06-16
KR100549137B1 (ko) 2006-02-03
NO996068L (no) 2000-02-11
ATE232522T1 (de) 2003-02-15
TR199903034T2 (xx) 2000-06-21
US7268140B2 (en) 2007-09-11
AU8625898A (en) 1998-12-30
HUP0003929A3 (en) 2001-08-28
JP2002503239A (ja) 2002-01-29
WO1998056771A2 (en) 1998-12-17
US6555537B2 (en) 2003-04-29
EA004038B1 (ru) 2003-12-25
US20030139425A1 (en) 2003-07-24
EP1254899B1 (en) 2005-05-25
US20020177598A1 (en) 2002-11-28
NO20031373D0 (no) 2003-03-26
EE200200684A (et) 2003-04-15
CZ295784B6 (cs) 2005-11-16
DE69830341D1 (de) 2005-06-30
PT1254899E (pt) 2005-10-31
IL132398A0 (en) 2001-03-19
CA2293382C (en) 2008-03-11
WO1998056771A3 (en) 1999-03-11
US6207665B1 (en) 2001-03-27
KR20010013703A (ko) 2001-02-26
ES2191320T3 (es) 2003-09-01
EA200200262A1 (ru) 2002-06-27
HUP0003929A2 (hu) 2001-05-28
US6541476B1 (en) 2003-04-01
US20060135487A1 (en) 2006-06-22
SK285162B6 (sk) 2006-07-07
CA2293382A1 (en) 1998-12-17
US20030158205A1 (en) 2003-08-21
SK171399A3 (en) 2000-09-12
NO996068D0 (no) 1999-12-09
US6573266B1 (en) 2003-06-03
IL132398A (en) 2004-08-31
EE9900565A (et) 2000-06-15
CZ448199A3 (cs) 2000-04-12
EE200200683A (et) 2003-04-15
IS2241B (is) 2007-05-15
EP0988292B1 (en) 2003-02-12
EP1254899A2 (en) 2002-11-06
IS5258A (is) 1999-11-19
US6972290B2 (en) 2005-12-06
DE69830341T2 (de) 2006-02-02
NO317343B1 (no) 2004-10-11
DE69811363D1 (de) 2003-03-20
DK1254899T3 (da) 2005-09-05
EE200200682A (et) 2003-04-15
EP0988292A2 (en) 2000-03-29
ES2242824T3 (es) 2005-11-16
EP1254899A3 (en) 2003-02-19
EA199901063A1 (ru) 2001-04-23
SK285445B6 (sk) 2007-01-04

Similar Documents

Publication Publication Date Title
ATE296292T1 (de) Piperazin-derivate und ihre verwendung als entzündungshemmende mittel
DE69524400D1 (de) Neue carbamate und harnstoffderivate als modifikatoren der multidrugresistenz
NO20032254L (no) Forbindelser for inhibering av ekspresjon av VACM-I
PT896533E (pt) Pentafluorobenzenosulfonamidas e analogos
ATE221885T1 (de) Substituierte sulfonylphenylheterocyclen als cyclooxygenase-2 und 5- lipoxygenase inhibitoren
DE69910831D1 (de) Epothilonderivate und ihre verwendung als antitumormittel
DE60027913D1 (de) 5-beta-sapogenin und pseudosapogeninderivate und ihre verwendung zur behandlung von demenz
DE69528710D1 (de) 2-substituierte 1,2,5-thiadiazolidin-3-on-1,1-dioxiden, zusammensetzung und deren verwendung
DE69839939D1 (de) Tropoelastinderivate
DE69725457D1 (de) Piperazinderivate als neurokinin-antagonisten
AR020563A1 (es) Compuestos (poli)tia-alquinoicos y sus derivados, composiciones que los incluyen y su utilizacion
ATE260258T1 (de) Substituierte isochinoline derivate und ihre verwendung als anticonvulsiva
ATE256685T1 (de) Anellierte pyrrolverbindungen, diese enthaltende pharmazeutische mittel und deren verwendung
ATE263139T1 (de) 3-alkoxylbenzylaminderivate und ihre verwendung als arzneimittel zur behandlung von schizophrenie
TR200000916T2 (tr) İkameli piperidin türevleri.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1254899

Country of ref document: EP

REN Ceased due to non-payment of the annual fee